Literature DB >> 29507802

New horizons from immunotherapy in malignant pleural mesothelioma.

Luana Calabrò1, Giulia Rossi1, Michele Maio1.   

Abstract

Malignant pleural mesothelioma (MPM) is an aggressive disease with a severe prognosis. Medical treatment for MPM unresectable patients is still unsatisfactory; therefore novel therapeutic approaches are urgently needed. Immunotherapy represents a promising treatment for MPM patients. Here, we'll discuss the most promising immunotherapeutic treatments currently under active investigation for this still dreadful disease.

Entities:  

Keywords:  Mesothelioma; immune-checkpoints; immunotherapy

Year:  2018        PMID： 29507802      PMCID： PMC5830566          DOI： 10.21037/jtd.2017.12.88

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


  46 in total

1.  Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.

Authors:  Luana Calabrò; Aldo Morra; Ester Fonsatti; Ornella Cutaia; Carolina Fazio; Diego Annesi; Marica Lenoci; Giovanni Amato; Riccardo Danielli; Maresa Altomonte; Diana Giannarelli; Anna Maria Di Giacomo; Michele Maio
Journal:  Lancet Respir Med       Date:  2015-03-26       Impact factor: 30.700

Review 2.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

Review 3.  PD-1 and PD-L1 antibodies in cancer: current status and future directions.

Authors:  Arjun Vasant Balar; Jeffrey S Weber
Journal:  Cancer Immunol Immunother       Date:  2017-02-17       Impact factor: 6.968

4.  Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients.

Authors:  B Castagneto; S Zai; L Mutti; A Lazzaro; R Ridolfi; E Piccolini; A Ardizzoni; L Fumagalli; G Valsuani; M Botta
Journal:  Lung Cancer       Date:  2001 Feb-Mar       Impact factor: 5.705

5.  Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.

Authors:  Gérard Zalcman; Julien Mazieres; Jacques Margery; Laurent Greillier; Clarisse Audigier-Valette; Denis Moro-Sibilot; Olivier Molinier; Romain Corre; Isabelle Monnet; Valérie Gounant; Frédéric Rivière; Henri Janicot; Radj Gervais; Chrystèle Locher; Bernard Milleron; Quan Tran; Marie-Paule Lebitasy; Franck Morin; Christian Creveuil; Jean-Jacques Parienti; Arnaud Scherpereel
Journal:  Lancet       Date:  2015-12-21       Impact factor: 79.321

6.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

Review 7.  Mesothelin-targeted agents in clinical trials and in preclinical development.

Authors:  Ronan J Kelly; Elad Sharon; Ira Pastan; Raffit Hassan
Journal:  Mol Cancer Ther       Date:  2012-02-17       Impact factor: 6.261

8.  Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P.

Authors:  Robert J Kreitman; Raffit Hassan; David J Fitzgerald; Ira Pastan
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

9.  Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.

Authors:  Luana Calabrò; Aldo Morra; Ester Fonsatti; Ornella Cutaia; Giovanni Amato; Diana Giannarelli; Anna Maria Di Giacomo; Riccardo Danielli; Maresa Altomonte; Luciano Mutti; Michele Maio
Journal:  Lancet Oncol       Date:  2013-09-11       Impact factor: 41.316

10.  Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma.

Authors:  Robin Cornelissen; Lysanne A Lievense; Alexander P Maat; Rudi W Hendriks; Henk C Hoogsteden; Ad J Bogers; Joost P Hegmans; Joachim G Aerts
Journal:  PLoS One       Date:  2014-09-05       Impact factor: 3.240
View more
  3 in total

Review 1.  Is there a role for immunotherapy in malignant pleural mesothelioma?

Authors:  Alfredo Tartarone; Rosa Lerose; Michele Aieta
Journal:  Med Oncol       Date:  2018-05-29       Impact factor: 3.064

Review 2.  A Review of Pharmacologic Management in the Treatment of Mesothelioma.

Authors:  Eric P Borrelli; Conor G McGladrigan
Journal:  Curr Treat Options Oncol       Date:  2021-01-12

Review 3.  Prognostic value of maximum standard uptake value, metabolic tumour volume, and total lesion glycolysis of 18F-FDG PET/CT in patients with malignant pleural mesothelioma: a systematic review and meta-analysis.

Authors:  Weibo Wen; Dongyuan Xu; Yongnan Piao; Xiangdan Li
Journal:  Cancer Cell Int       Date:  2022-02-03       Impact factor: 5.722
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.